ResultsIQ › Latest results › Eris Lifesciences Limited

Eris Lifesciences Limited Q3 FY26 results deck summary

NSE: ERIS · BSE: 540596

Results deck of 13 Feb 2026, summarised by AI from the filing.

Q3 FY26 consolidated revenue ₹807 cr. (up 11% yoy); FY26 guidance revenue ~₹3,200 cr. and EBIDTA ~₹1,150 cr.

Key takeaways

Q3 revenue Consolidated revenue ₹807 cr. (up 11% yoy); 9M revenue ₹2,373 cr. (up 8.4% yoy)

Eris Lifesciences Limited Q1 FY27 results

As filed: Revenue ₹873 cr (+13% year on year), EBITDA ₹296 cr (+7% year on year), PAT ₹143 cr (+15% year on year), EBITDA margin 33.9% (−191 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

Q4 FY26: Revenue ₹757 cr (+7% year on year), EBITDA ₹274 cr (+9% year on year), PAT ₹279 cr (+174% year on year), EBITDA margin 36.2% (+42 bps). Score 38 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was well above it. EBITDA margin rose 42 bps year on year. Tax rate -75%. Consolidated profit +174% but standalone -129%. Revenue fell 6% from last quarter. Share price after the results: +8.4% in 30 days (Nifty 500: +2.8%).
Q3 FY26: Revenue ₹807 cr (+11% year on year), EBITDA ₹282 cr (+13% year on year), PAT ₹109 cr (+40% year on year), EBITDA margin 34.9% (+49 bps). Score 40 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit before exceptional items growth was above it. EBITDA margin rose 49 bps year on year. Profit fell 6% from last quarter. Share price after the results: −12.5% in 28 days (Nifty 500: −9.6%).
Q2 FY26: Revenue ₹792 cr (+7% year on year), EBITDA ₹288 cr (+10% year on year), PAT ₹134 cr (+40% year on year), EBITDA margin 36.4% (+105 bps). Score 39 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was well above it. EBITDA margin rose 105 bps year on year. Share price after the results: −1.5% in 30 days (Nifty 500: +0.2%).
Q1 FY26: Revenue ₹773 cr (+7% year on year), EBITDA ₹277 cr (+11% year on year), PAT ₹125 cr (+40% year on year), EBITDA margin 35.8% (+125 bps). Score 40 of 100, In line with trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was well above it. EBITDA margin rose 125 bps year on year. Revenue rose ₹53.0 cr on a year ago, against ₹253 cr the year before. Share price after the results: −2.2% in 30 days (Nifty 500: −0.2%).
Q4 FY25: Revenue ₹705 cr (+28% year on year), EBITDA ₹252 cr (+69% year on year), PAT ₹102 cr (+28% year on year), EBITDA margin 35.7% (+870 bps). Score 72 of 100, Above trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 870 bps year on year. Consolidated profit +27% but standalone -25%. Revenue fell 3% from last quarter. Revenue rose ₹154 cr on a year ago, more than the ₹148 cr it added the year before. Share price after the results: +23.3% in 30 days (Nifty 500: +0.3%).
Q3 FY25: Revenue ₹727 cr (+50% year on year), EBITDA ₹250 cr (+42% year on year), PAT ₹87.0 cr (−14% year on year), EBITDA margin 34.4% (−183 bps). Score 66 of 100, Above trend. Revenue and EBITDA growth were above the company's own trend; profit growth was below it. EBITDA margin fell 183 bps year on year. Profit fell 9% from last quarter. Revenue rose ₹241 cr on a year ago, more than the ₹63.0 cr it added the year before.
Q2 FY25: Revenue ₹739 cr (+46% year on year), EBITDA ₹261 cr (+44% year on year), PAT ₹96.0 cr (−21% year on year), EBITDA margin 35.3% (−52 bps). Score 65 of 100, Above trend. EBITDA margin fell 52 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Eris Lifesciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.